Shinkin Capital

Shinkin Capital, established in 2001 and based in Tokyo, Japan, operates as a growth equity firm focused on small and medium-sized enterprises (SMEs). As a group company of Shinkin Central Bank, it plays a crucial role within the credit union industry, providing investment and advisory services tailored to the unique needs of SMEs. The firm aims to support these businesses by supplying equity funds and offering M&A brokerage advisory services, addressing challenges faced by SMEs and helping them create new value. Shinkin Capital is committed to fostering growth and development within the SME sector, aligning its efforts with the broader objectives of the credit union and banking ecosystem.

Keisuke Izutsu

President and CEO

Past deals in CAD

Instalimb

Series B in 2025
Instalimb, Inc. is a pioneering company based in Tokyo, Japan, specializing in the development of low-cost 3D printed prosthetics and orthotics. Leveraging advanced 3D-CAD, 3D printing, and machine learning technologies, Instalimb aims to revolutionize the prosthetics industry by significantly reducing production costs and delivery times. The company utilizes an innovative algorithm that enhances design efficiency, allowing for the creation of customized prosthetic devices tailored to individual needs. This cutting-edge approach not only makes prosthetics more accessible to amputees but also represents a significant advancement in the field of assistive technology. As the world's first business dedicated to 3D printed prostheses, Instalimb is committed to improving the quality of life for individuals requiring these essential devices.

Hira Tech

Venture Round in 2015
Hira Tech manufactures parts for machine tools and housings for processing stainless steel and steel materials. It specializes in high-mix low-volume production and ultra-quick delivery through CAD-CAM collaboration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.